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Abstract
Background
Radiotherapy is increasingly used to treat oligometastatic patients. We sought to identify
prognostic criteria in oligometastatic patients undergoing definitive hypofractionated image-
guided radiotherapy (HIGRT).
Methods
Exclusively extracranial oligometastatic patients treated with HIGRT were pooled. Characteris-
tics including age, sex, primary tumor type, interval to metastatic diagnosis, number of treated
metastases and organs, metastatic site, prior systemic therapy for primary tumor treatment,
prior definitive metastasis-directed therapy, and systemic therapy for metastasis associated
with overall survival (OS), progression-free survival (PFS), and treated metastasis control
(TMC) were assessed by the Cox proportional hazards method. Recursive partitioning analysis
(RPA) identified prognostic risk strata for OS and PFS based on pretreatment factors.
Results
361 patients were included. Primary tumors included non-small cell lung (17%), colorectal
(19%), and breast cancer (16%). Three-year OS was 56%, PFS was 24%, and TMC was
72%. On multivariate analysis, primary tumor, interval to metastases, treated metastases
number, and mediastinal/hilar lymph node, liver, or adrenal metastases were associated
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with OS. Primary tumor site, involved organ number, liver metastasis, and prior primary dis-
ease chemotherapy were associated with PFS.
OS RPA identified five classes: class 1: all breast, kidney, or prostate cancer patients
(BKP) (3-year OS 75%, 95% CI 66–85%); class 2: patients without BKP with disease-free
interval of 75+ months (3-year OS 85%, 95% CI 67–100%); class 3: patients without BKP,
shorter disease-free interval, two metastases, and age < 62 (3-year OS 55%, 95% CI 48–
64%); class 4: patients without BKP, shorter disease-free interval, three metastases, and
age < 62 (3-year OS 38%, 95% CI 24–60%); class 5: all others (3-year OS 13%, 95% CI
5–35%). Higher biologically effective dose (BED) (p < 0.01) was associated with OS.
Conclusions
We identified clinical factors defining oligometastatic patients with favorable outcomes, who
we hypothesize are most likely to benefit from metastasis-directed therapy.
Introduction
Metastases remain the leading cause of cancer death worldwide. Metastatic patients are rou-
tinely treated with systemic therapy based on the hypothesis that the presence of a single
metastasis is universally associated with subclinical micrometastases. However, data and expe-
rience suggest that malignant disease burden ranges in spectrum from locoregionally confined
disease to widespread distant metastases [1]. Included in this continuum are oligometastatic
(OM) patients with metastases limited in number and destination organ who may have a more
indolent disease course [2]. Ablative metastasis-directed therapies to all known tumors in OM
patients hypothetically could prolong disease-free interval and overall survival. Metastasis-
directed therapy of focal OM was first described in surgical series, resulting in long-term dis-
ease control and survival for some patients [3,4].
Technological advancements enable the delivery of fewer, more precisely targeted, high
radiation doses with steep dose gradients between targets and normal tissues. These radiosur-
gical-style treatments initially used for brain tumors have expanded to extracranial use. Com-
monly termed stereotactic body radiotherapy (SBRT) but perhaps more precisely and broadly
called hypofractionated image-guided radiotherapy (HIGRT), these treatments are now a stan-
dard for many different diseases with high treated-tumor control rates, including non-small
cell lung cancer (NSCLC), hepatocellular carcinoma, pancreatic cancer, and prostate cancer
[5–9].
With advances in radiation techniques enabling treatment of multiple tumor sites in the
same patient [10], HIGRT is increasingly being used to treat all known OM [11]. Prospective
studies of OM patients treated with HIGRT report promising rates of treated metastasis con-
trol (TMC) and acceptable toxicity rates [12–22]. In these often heavily pretreated populations,
similar long-term survival rates as surgical series are seen [23]. However, most patients experi-
ence cancer progression [24].
Therefore, optimizing patient selection is critical to define those OM patients most likely to
benefit from HIGRT. Although tissue-based biomarkers of the oligometastatic state are begin-
ning to be described, they are not yet ready to be used for patient selection [25–27]. Ongoing
randomized trials use only the number of metastases as inclusion criteria. However, given the
growing experience treating oligometastases with HIGRT, we hypothesized that other pretreat-
ment (baseline) clinical criteria may exist across different diseases to better define the OM
Prognostic system for oligometastases
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patients most likely to have long-term survival and benefit from metastases-directed therapy.
Therefore, we performed a hypothesis-generating analysis of individual patients pooled from
multiple institutional experiences, including several prospective trials to identify these criteria.
Materials and methods
Patient cohort
Consecutive exclusively extracranial OM ( 5 metastases) patients treated with definitive-
intent radiation to all metastases comprised the study population. Our cohort included
patients from multiple prospective clinical trials, including a dose escalation trial [15,28], two
prospective pilot studies [14,18], and a phase I/II study of concurrent sunitinib and HIGRT
[13,29], as well as patients treated off protocol, but per prior protocols. Patients could receive
concurrent non-anthracycline based systemic agents, including sunitinib on protocol. Patients
on or off protocol could have had any prior therapy, including definitive metastasis-directed
therapy with curative intent or palliative systemic therapy, per the standards of their treating
institution. All local institutional review boards (University of Chicago, University of Roches-
ter, Mt. Sinai, Wake Forest University, and the Durham VA) approved this study. Informed
consent was obtained for the prospective studies that have been previously published and
waived for this pooled analysis.
Treatment and follow-up
Treatment was per institutional protocols as previously described [13–15,18,28,29]. All
patients underwent computed tomography (CT)-based treatment planning in customized
immobilization devices with respiratory motion assessment and management where appropri-
ate. The intent of all treatments was to deliver ablative doses to all known metastases. Dose-
fractionation schedule varied, with common schedules including ten fractions of 5–6 Gy per
fraction, or three fractions ranging from 8–16 Gy per fraction. Patients were followed at stan-
dard (approximately 3 month) intervals for toxicity and disease control assessment with physi-
cal examination and volumetric imaging including CT and/or PET scanning. Overall survival
(OS), progression-free survival (PFS), and treated metastasis control (TMC), on a per patient
basis, were defined from the time of HIGRT. PFS was defined as the time to death or any
tumor progression, either at a treated metastasis or distant site. TMC was defined as the time
to progression at any treated metastasis within a patient. Progression was defined based on the
Response Evaluation Criteria in Solid Tumors (RECIST) [30] in the prospective studies [13–
15,18,28,29] and based on retrospective review of imaging and clinical documentation for
patients who were not treated on trial.
Statistical analysis
The objective of this retrospective hypothesis-generating pooled analysis was to develop crite-
ria for prognostic risk groups for OS. Statistics were performed in R version 3.3.1 (R Founda-
tion) and source code is included in supplement (S1 File, S2 File) and on GitHub[31]. All
statistical tests were 2-sided with significance at p< 0.05. For all OS and PFS analyses, age, sex,
primary tumor site, interval to metastasis diagnosis, number of metastases treated, number of
treated organs, location of metastasis, prior chemotherapy for primary treatment, prior defini-
tive metastasis-directed therapy, or prior systemic therapy for metastasis were considered.
Because data regarding systemic agents were not uniformly collected, this was not included in
the analysis. Analysis of TMC did not include age and sex as they were not hypothesized to
impact TMC.
Prognostic system for oligometastases
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OS, PFS, and TMC were assessed with the Kaplan-Meier method, and assessment of vari-
ables impacting OS, PFS, and TMC was performed with univariate and multivariate Cox pro-
portional hazards models. Parsimonious multivariate Cox proportional hazards models for
each were constructed based on hypothesized clinical relevance, results of univariate analysis,
and consideration of stepwise backward regression. The proportional hazards assumption was
verified for all individual variables in the final multivariate models by the relationship between
Schoenfield residuals. All models additionally globally met the proportional hazards assump-
tion with the exception of PFS. Nonlinearity was assessed with plot of Martingale residuals
of the null Cox model for continuous variables in the final OS model (time to metastasis).
Patients with missing data were excluded in generating the corresponding univariate and mul-
tivariate models.
The binary classification tree approach with recursive partitioning analysis (RPA) was
implemented to stratify the patients into risk groups based on OS. The intent of RPA was to
identify pre-treatment prognostic classes. Age, sex, primary tumor type, interval to metastasis,
number of metastases treated, number of treated organs, location of metastasis, prior chemo-
therapy for primary treatment, prior definitive metastasis-directed therapy (with either oligo-
progressive disease at a treated or new untreated site), or systemic therapy for metastasis were
considered as candidates by the RPA calculation, which stratifies based on stepwise binary
division of groups based on variables that have more homogeneous outcomes [32]. This is
repeated until binary divisions are no longer possible. To minimize overfitting and improve
generalizability, the tree was pruned with a cost complexity parameter of 0.018 based on plot-
ting against the cross-validation error. The terminal nodes of the classification tree were
selected as the prognostic risk groups. The same procedure was repeated to generate a decision
tree based on PFS with a complexity parameter of 0.038. TMC cross-validation error did not
reach a local minimum and thus a generalizable model could not be generated. Due to the
need for sufficient patients to sufficiently power a hypothesis-generating RPA model, the deci-
sion was made to incorporate all patients in the creation of the model rather than using them
in a separate validation set.
We also performed an analysis of the relationship between biologically effective dose (BED)
and OS, PFS, and TMC, as well as that between TMC and OS and PFS. BED was calculated
assuming an alpha-beta ratio of 10 Gy.
BEDa
b
¼ N x d x 1þ
d
a
b
 
2
4
3
5
As different metastases in the same patient could be treated with different doses, the lowest
BED per patient was used for this analysis. This was chosen to be as conservative as possible.
OS, PFS, and TMC endpoints were analyzed in a univariate fashion based on stratification of
BED of 75 Gy or higher (the median BED of the cohort as well as a well-established dose com-
monly used for patients off protocol[14,18]) with the Kaplan-Meier method and log-rank test.
BED and TMC were also included in the final multivariate Cox proportional hazards models
for the appropriate endpoints to consider other contributing variables.
Results
Outcomes of oligometastatic patients following HIGRT
The multi-institutional cohort included a total of 361 patients. Baseline patient characteristics
are presented in Table 1. The median follow-up was 26.2 months (35.9 for surviving patients).
Primary tumor types included NSCLC (17%), colorectal cancer (19%), and breast cancer
Prognostic system for oligometastases
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(16%). Median time to metastases from initial cancer diagnosis was 12.0 months. Most patients
received prior systemic therapy including 74% for primary disease treatment and 70% for met-
astatic disease. Thirty percent received prior definitive metastasis-directed therapy.
For the entire cohort, median OS was 47.1 months and 3-year OS was 56% (Fig 1A).
Median PFS was 10.1 months and 3-year PFS was 24%, which plateaued with a 22% PFS at
5-years (Fig 1B). Median TMC was not reached and 3-year TMC was 72% (Fig 1C). On uni-
variate analysis, Cox proportional hazards models indicated that compared to breast cancer
patients, those with colorectal, other GI, NSCLC, sarcoma, and other primary tumor types had
significantly shorter OS (Table 2). Other characteristics such as shorter interval to metastatic
diagnosis, greater number of treated metastases, greater number of treated organs, hilar or
Table 1. Baseline demographics and clinical characteristics.
Total (n = 361)
Variable Median (Interquartile range)/
Patients (%)
Age (years) 62.7 (54.0–71.0)
Sex
Male 188 (52%)
Female 173 (48%)
Primary tumor type
Breast 56 (16%)
Colorectal 69 (19%)
Other gastrointestinal 34 (9%)
Head and neck 34 (9%)
Kidney 25 (7%)
Non-small cell lung cancer 62 (17%)
Prostate 11 (3%)
Sarcoma 22 (6%)
Other 48 (13%)
Interval to metastatic diagnosis (mos) 12.0 (1.00–36.0)
Number of metastases treated 2 (1–3)
Number of organs treated 1 (1–1)
Metastatic sites (patients may have more than 1)
Lung 170
Hilum/mediastinum 40
Liver 100
Adrenal 19
Bone 71
Abdominal/pelvic lymph nodes 23
Prior chemotherapy for primary disease 237 (74%)
Prior definitive metastasis-directed therapy 108 (30%)
Prior systemic therapy for metastatic disease 253 (70%)
BED 75 Gy (65.25–94.5)
Treated on clinical trial 243 (67%)
Other primary tumor types included: small-cell lung cancer, gynecologic malignancies, carcinoid and
neuroendocrine tumors, skin cancer, urinary bladder cancer, adrenocortical carcinoma, malignant peripheral nerve
sheath tumor, parathyroid cancer, hemangiopericytoma, thymoma, pituitary malignancy.
Among those patients with complete information (320)
https://doi.org/10.1371/journal.pone.0195149.t001
Prognostic system for oligometastases
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mediastinal lymph node metastasis, and liver metastases were associated with shorter OS.
With adjustment on multivariate analysis, primary tumor type, interval to metastatic diagno-
sis, number of treated metastases, and mediastinal or hilar lymph node, liver, or adrenal metas-
tases were independently significant.
PFS data was available for 314 patients. On univariate analysis, primary tumor type was
associated with PFS, as was number of treated metastases, number of treated organs, liver
metastases, and prior primary disease chemotherapy (Table 3). Multivariate analysis demon-
strated that primary tumor site, number of involved organs, liver metastasis, and prior primary
disease chemotherapy were independent predictors of PFS.
Fig 1. Overall and progression free survival, treated metastasis control for all 361 oligometastatic patients treated with ablative radiotherapy. Median
survival was 47.1 months and 3-year survival was 56% (A). Median progression-free survival was 10.1 months and 3-year progression-free survival was 24%
(B). Median treated metastasis control was not reached and 3-year TMC was 72% (C).
https://doi.org/10.1371/journal.pone.0195149.g001
Prognostic system for oligometastases
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TMC data was available and analyzed for 317 patients. Univariate analysis suggested that
primary tumor type, number of treated metastases and number of treated organs, liver metas-
tasis, non-bone metastasis, and systemic therapy for metastatic disease were associated with
TMC (Table 4). With multivariate adjustment, primary tumor type, hilar/mediastinal or liver
metastasis, and systemic therapy for metastasis were associated with TMC.
Identifying prognostic cohorts via recursive partitioning
Recursive partitioning analysis identified five prognostic classes for overall survival. (Fig 2A
and 2B). Class 1 (3-year OS 75%, 95% CI 66–85%) consisted of all breast, kidney, or prostate
cancer patients (BKP), which RPA separated as distinct from other primary tumor types.
Without pruning, RPA suggested that solitary metastasis BKP patients may have superior OS
to those with> one metastasis. However, this did not remain following the tree pruning pro-
cess based on cross-validation error, and thus RPA was unable to further identify prognostic
subclasses within class 1. Class 2 (3-year OS 85%, 95% CI 67–100%) included all patients with
other diseases but with disease-free interval of 75 months. Patients with non-BKP disease,
shorter disease-free interval (< 75 months),2 metastases comprised class 3 (3-year OS 55%,
Table 2. Univariate and multivariate analysis of overall survival (OS).
Univariate Multivariate
Pre-treatment Treatment
BED model
Variable HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 0.99 (0.99–1.01) 0.69
Female sex 0.98 (0.73–1.32) 0.89
Primary tumor type
Breast Ref Ref Ref
Colorectal 1.98 (1.12–3.52) 0.02 1.83 (0.97–3.44) 0.06 2.18 (1.14–4.14) 0.02
Other gastrointestinal 3.49 (1.85–6.58) <0.01 3.80 (1.84–7.86) <0.01 4.30 (2.06–8.96) <0.01
Head and neck 1.77 (0.89–3.52) 0.10 1.81 (0.80–4.10) 0.15 1.93 (0.86–4.37) 0.11
Kidney 0.95 (0.39–2.30) 0.91 1.14 (0.44–3.00) 0.79 1.39 (0.53–3.67) 0.51
Non-small cell lung cancer 2.63 (1.46–4.76) <0.01 2.58 (1.32–5.02) <0.01 3.17 (1.60–6.29) <0.01
Prostate 0.30 (0.04–2.27) 0.24 Insufficient events
Sarcoma 2.16 (1.07–4.33) 0.03 2.66 (1.25–5.64) 0.01 2.99 (1.40–6.36) <0.01
Other 2.01 (1.09–3.72) 0.03 2.75 (1.40–5.40) <0.01 2.90 (1.49–5.66) <0.01
Interval to metastasis (month) 0.99 (0.98–0.99) <0.01 0.99 (0.98–0.997) <0.01 0.99 (0.98–0.997) <0.01
Number of metastases treated 1.34 (1.19–1.51) <0.01 1.31 (1.12–1.53) <0.01 1.35 (1.16–1.58) <0.01
Number of organs treated 1.60 (1.22–2.10) <0.01
Any lung metastasis 0.94 (1.07–1.27) 0.68
Any hilar or mediastinal lymph node metastasis 1.84 (1.18–2.86) <0.01 1.84 (1.06–3.21) 0.03 1.49 (0.85–2.61) 0.17
Any liver metastasis 1.45 (1.06–1.99) 0.02 1.55 (1.04–2.29) 0.03 1.44 (0.97–2.14) 0.07
Any adrenal metastasis 1.70 (0.92–3.13) 0.09 2.27 (1.13–4.54) 0.02 1.92 (0.95–3.91) 0.07
Any bone metastasis 0.76 (0.50–1.15) 0.19 1.65 (0.99–2.75) 0.05 1.19 (0.83–2.06) 0.53
Any abdominal or pelvic lymph node metastasis 1.18 (0.60–2.31) 0.64
Prior chemotherapy for primary disease 1.32 (0.90–1.95) 0.16
Prior definitive metastasis-directed therapy 0.86 (0.62–1.20) 0.37
Prior systemic therapy for metastasis 1.23 (0.88–1.71) 0.24
BED 75 or greater 0.69 (0.44–0.82) <0.01 0.49 (0.33–0.72) <0.01
Abbreviations: BED, biologically effective dose.
https://doi.org/10.1371/journal.pone.0195149.t002
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95% CI 48–64%). Class 4 (3-year OS 38%, 95% CI 24–60%) included patients with non-BKP
disease, shorter disease-free interval, 3 metastases, and age<62. Finally, class 5 included all
remaining patients (3-year OS 13%, 95% CI 5–35%). These differences in overall survival were
statistically significant (log-rank p< 0.01). Based on Cox proportional hazards with class 1 as
the reference, hazard ratios (HR) were as follows: class 2 0.20 (95% CI 0.04–0.92; p = 0.04),
class 3 2.35 (95% CI 1.50–3.67; p< 0.01), class 4 3.51 (1.96–6.29; p< 0.01), and class 5 9.36
(95% CI 5.38–16.27; p< 0.01).
For PFS, RPA defined only two prognostic classes as shown in Fig 2C and 2D based on pri-
mary tumor type; class 1 (3-year PFS 44%, 95% CI 32–57%): BKP and class 2 (3-year PFS 17%,
95% CI 13–23%): all other non-BKP primary tumor types; log-rank p< 0.01. On Cox propor-
tional hazards, this result was also statistically significant (HR 2.40 with class 1 as reference,
95% CI 1.73–3.34; p< 0.01).
Impact of BED on survival
Univariate stratification by BED suggested a correlation between minimum BED> 75 Gy
with OS, PFS, and TMC. Those treated with BED of 75 had a 3-year OS of 61% (95% CI 55–
Table 3. Univariate and multivariate analysis of progression-free survival (PFS).
Univariate Multivariate
Pre-treatment Treatment
BED model
Variable HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 1.00 (0.99–1.01) 0.49
Female sex 0.89 (0.69–1.15) 0.37
Primary tumor type
Breast Ref Ref Ref
Colorectal 2.18 (1.38–3.45) <0.01 2.09 (1.32–3.31) <0.01 2.48 (1.53–4.01) <0.01
Other gastrointestinal 2.65 (1.49–4.71) <0.01 2.88 (1.60–5.21) <0.01 3.24 (1.78–5.89) <0.01
Head and neck 2.87 (1.62–5.09) <0.01 3.96 (2.19–7.17) <0.01 4.34 (2.39–7.87) <0.01
Kidney 1.36 (0.73–2.56) 0.34 2.03 (1.04–3.96) 0.04 2.38 (1.21–4.71) 0.01
Non-small cell lung cancer 2.30 (1.43–3.70) <0.01 2.73 (1.68–4.46) <0.01 3.05 (1.86–5.00) <0.01
Prostate 0.26 (0.04–1.92) 0.19 0.44 (0.06–3.28) 0.42 0.47 (0.06–3.53) 0.46
Sarcoma 3.25 (1.83–5.79) <0.01 4.05 (2.24–7.32) <0.01 4.85 (2.64–8.90) <0.01
Other 2.57 (1.56–4.25) <0.01 3.03 (1.82–5.04) <0.01 3.22 (1.93–5.36) <0.01
Interval to metastasis (month) 0.999 (0.999–1.00) 0.53
Number of metastases treated 1.18 (1.06–1.31) <0.01
Number of organs treated 1.47 (1.16–1.86) <0.01 1.42 (1.12–1.80) <0.01 1.36 (1.07–1.72) 0.01
Any lung metastasis 1.00 (1.00–0.77) 0.997
Any hilar or mediastinal lymph node metastasis 1.34 (0.91–1.98) 0.14
Any liver metastasis 1.39 (1.06–1.82) 0.02 1.45 (1.07–1.97) 0.02 1.44 (1.06–1.94) 0.02
Any adrenal metastasis 1.56 (0.91–2.68) 0.11
Any bone metastasis 0.77 (0.54–1.11) 0.16
Any abdominal or pelvic lymph node metastasis 1.35 (0.80–2.27) 0.27
Prior chemotherapy for primary disease 1.47 (1.08–1.99) 0.01 1.57 (1.13–2.19) 0.01 1.48 (1.06–2.07) 0.02
Prior definitive metastasis-directed therapy 0.93 (0.70–1.24) 0.63
Prior systemic therapy for metastasis 1.23 (0.92–1.65) 0.16
BED 75 or greater 0.77 (0.58–1.01) 0.06 0.66 (0.49–0.89) 0.01
Abbreviations: BED, biologically effective dose.
https://doi.org/10.1371/journal.pone.0195149.t003
Prognostic system for oligometastases
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68%) compared to 43% (95% CI 34–54%) for those treated with BED < 75 (p< 0.01; Fig 3A).
Three-year PFS for BED75 Gy was 27% (95% CI 21–34%) versus 18% (95% CI 11–29%) for
BED< 75 (p = 0.06; Fig 3B). With BED75 Gy, 3-year TMC was 78% (95% CI 72–84%), sig-
nificantly higher than that with BED<75 Gy, 55% (95% CI 44–68%); p< 0.01 (Fig 3C). Incor-
porating BED into the multivariate OS model suggested a statistically significant association
(HR 0.49, 95% CI 0.33–0.72; p< 0.01; Table 2). This adjusted model including both BED and
site of metastasis had a decreased effect size and significance of liver, adrenal, and bone metas-
tases, suggesting potential correlation between higher BED and these treated sites (HR 1.49
(0.85–2.61); p = 0.17). Similarly, the adjusted model for PFS (Table 3) suggested a statistically
significant association with BED (HR 0.66, 95% CI 0.49–0.89; p = 0.01). In contrast, this
appeared independent of other variables in the PFS model.
Discussion
In this large multi-institutional cohort of exclusively extracranial OM patients treated with
definitive HIGRT, we found a median progression free survival approaching 1 year and a
median overall survival approaching 4 years. Furthermore, 40% of patients were alive 6 years
after metastasis directed therapy with ~20% alive without progression. These data are similar
Table 4. Univariate and multivariate analysis of per patient treated metastasis control (TMC).
Univariate Multivariate
Pre-treatment Treatment
BED model
Variable HR (95% CI) p HR (95% CI) p HR (95% CI) p
Primary tumor type
Breast Ref Ref Ref
Colorectal 2.53 (1.22–5.24) 0.01 3.03 (1.43–6.43) <0.01 4.71 (2.12–10.46) <0.01
Other gastrointestinal 2.41 (0.95–6.12) 0.06 4.15 (1.57–10.99) <0.01 5.30 (1.98–14.18) <0.01
Head and neck 0.66 (0.18–2.38) 0.52 1.21 (0.33–4.53) 0.77 1.31 (0.35–4.88) 0.68
Kidney 1.60 (0.58–4.41) 0.36 3.22 (1.12–9.24) 0.03 5.08 (1.70–15.21) <0.01
Non-small cell lung cancer 1.17 (0.48–2.80) 0.73 1.63 (0.67–3.98) 0.28 2.35 (0.95–5.84) 0.06
Prostate Insufficient events
Sarcoma 1.06 (0.33–3.38) 0.92 1.99 (0.60–6.56) 0.07 2.49 (0.76–8.20) 0.13
Other 1.66 (0.72–3.82) 0.24 2.16 (0.93–5.04) 0.02 2.64 (1.13–6.19) 0.02
Interval to metastasis (month) 0.999 (0.997–1.001) 0.32
Number of metastases treated 1.21 (1.01–1.45) 0.04
Number of organs treated 1.59 (1.10–2.30) 0.01
Any lung metastasis 0.91 (0.59–1.42) 0.68
Any hilar or mediastinal lymph node metastasis 1.69 (0.89–3.21) 0.11 2.42 (1.21–4.80) 0.01 2.12 (1.06–4.25) 0.03
Any liver metastasis 2.47 (1.59–3.85) <0.01 2.05 (1.25–3.36) <0.01 2.15 (1.32–3.49) <0.01
Any adrenal metastasis 0.44 (0.11–1.79) 0.25
Any bone metastasis 0.43 (0.20–0.94) 0.03
Any abdominal or pelvic lymph node metastasis 1.21 (0.49–3.00) 0.68
Prior chemotherapy for primary disease 1.72 (0.97–3.07) 0.07
Prior definitive metastasis-directed therapy 0.61 (0.35–1.06) 0.08 0.61 (0.35–1.08) 0.09 0.57 (0.32–1.01) 0.05
Prior systemic therapy for metastasis 2.38 (1.29–4.41) 0.01 2.17 (1.12–4.22) 0.02 1.75 (0.89–3.46) 0.10
BED 75 or greater 0.45 (0.29–0.70) <0.01 0.36 (0.22–0.59) <0.01
Abbreviations: BED, biologically effective dose.
https://doi.org/10.1371/journal.pone.0195149.t004
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to surgical metastasectomy series [3,4] suggesting a promising role for radiotherapy treating at
least limited metastatic patients not technically resectable or medically fit.
We also found specific prognostic factors associated with improved OS, PFS, and TMC. In
particular, primary tumor type, time to metastatic diagnosis, number of metastases, age, and
metastatic site were independently associated with overall survival. For progression free sur-
vival, primary tumor type, number of treated organs, prior chemotherapy for primary disease,
and treated liver metastases, were independent prognostic factors. Treated metastasis control
was associated with primary tumor type, location of metastasis, and prior systemic therapy for
Fig 2. Recursive partitioning models for overall survival and progression-free survival. For overall survival, recursive partitioning allowed stratification of
patients into five prognostic classes (A). Overall survival was well-stratified based on RPA class (B); log-rank p< 0.01. For progression-free survival, recursive
partitioning allowed stratification of patients into two prognostic classes (C). Progression-free survival was well-stratified based on RPA class (D); log-rank
p< 0.01.
https://doi.org/10.1371/journal.pone.0195149.g002
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metastasis. Further, we found that higher minimum BED was associated with clinical
outcomes.
Our series is unique amongst published reports of prognostic factors for oligometastatic
patients. First, we analyzed a large cohort of metastatic patients with a wide range of primary
tumors and a variety of exclusively extracranial OM sites. This provides a broader characteri-
zation of underlying characteristics common to all oligometastatic patients irrespective of
primary and secondary tumor sites. Second, the results of the OS RPA demonstrate the impor-
tance and interaction of the various pre-treatment prognostic factors identified by Cox pro-
portional hazards modeling. Patients in the most favorable risk group were those with breast,
Fig 3. Overall and progression free survival, treated metastasis control by minimum biologically effective dose (BED). BED75 Gy was associated with
greater overall survival (p< 0.01) (A) and treated metastasis control (p< 0.01) (C), with trend for progression free survival (p = 0.06) (B).
https://doi.org/10.1371/journal.pone.0195149.g003
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renal cell, and prostate cancer, consistent with findings of a small subcohort of this study [29].
RPA was unable to stratify this cohort further. This suggests that other hypothesized clinical
factors such as number of metastases, disease-free interval, age, or metastatic site may not play
as large of a role in prognosis for these patients.
These outcomes are favorable in comparison to historical trials, particularly in breast cancer
and renal cell carcinoma [24,33,34]. For instance, in a study randomizing patients with metastatic
breast cancer to paclitaxel with or without gemcitabine, 91% of patients enrolled had four meta-
static sites with PFS of 8–10 months [35]. While colorectal cancer has been previously suspected
to be a favorable disease site and has historically been treated aggressively, RPA did not pool this
with BKP diseases. This suggests that patients with colorectal cancer may be less uniformly favor-
able than BKP diseases and require consideration of additional factors.
For patients with other primary tumor types, a long disease-free interval ( 75 months
until metastasis development) portended a similarly favorable prognosis. Our cohort of these
patients, however, was limited to 14 patients and should be considered hypothesis-generating.
For patients with non-BKP primary tumors and shorter disease-free intervals, < three metas-
tases was a favorable prognostic factor. Furthermore, patients with non-BKP primaries, short
disease free-intervals, three or more metastases, and age 62 had nearly a four-fold risk of
death in comparison to the entire cohort average, and a nine-fold risk in comparison to
patients with BKP diseases. These findings are important as outcomes following metastasis-
directed therapy are promising for some, but many patients progress early, stressing the need
to better identify patients most likely to benefit.
Beyond the ability to stratify patients, long-term survival in the most favorable populations
suggests clinical criteria possibly predicting for a more advantageous biology. The three most
favorable classes all had a three-year OS>50%. This indicates that the presented criteria pre-
dict for long-term survivors who we hypothesize are the best candidates for aggressive metasta-
sis-directed therapies. However, the 38% 3-year OS of class 4 patients is better than expected
for many metastatic patients, indicating that there may be some patients in classes 4 and 5 who
could benefit from metastasis-directed therapy to all known metastases.
Prior studies identifying risk groups of OM patients have primarily focused on either spe-
cific treated organs or treatment of specific diseases and included intracranial metastases
[16,36–42]. Many large series have identified prognostic factors in cohorts of resected pulmo-
nary metastases [3], resected liver metastases [4,16,39], and oligometastatic NSCLC [37,38,43].
Our findings are concordant with and integrate the findings of these studies into a larger
framework. Primary tumor type is the key determining factor of our study, with various forms
of adenocarcinoma (breast and prostate) portending the best prognosis, consistent with prior
data [16]. Lengthy disease-free interval and fewer treated metastases are more detailed indica-
tors of metachronous metastases [16,36–39]. Performance status has been identified in two
studies [37,39] as a positive prognostic factor. Although unavailable in our cohort, most
patients were treated on protocols requiring high-performance status [13–15,18,28,29]. The
consistency of these findings across multiple studies [3,4,16,36–39] and treatment modalities is
encouraging. Our findings augment these prior results by demonstrating how the various
prognostic factors interact.
High-level evidence supporting ablative therapy for limited metastatic patients is beginning
to emerge. A prospective randomized trial recently showed a progression-free survival benefit
to consolidative radiation or surgery following systemic therapy for NSCLC patients with
three or fewer metastases [44], and thermal ablation of colorectal liver metastases improved
survival when given with chemotherapy over chemotherapy alone [45]. Furthermore, data sug-
gest cost-effectiveness of ablative metastasis directed therapy in specific clinical scenarios [46].
However, most patients still experience disease progression. Our data provide a useful and
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simple tool to aid practitioners in the selection of appropriate candidates for these increasingly
implemented treatments [11,47].
This study is limited by available data. Though a large, diverse, and multi-institutional
cohort, patients in this cohort were selected for treatment, which might influence the overall
results. Moreover, though the diversity of the cohort allows comparisons between a variety of
patients and diseases, specific groups are therefore smaller. Application of the prognostic
groups, while giving broad guidelines, may not reflect the complete intricacies within each
group. For instance, we are unable to capture differences between hormone sensitivity of pros-
tate cancer or biomarker status of breast cancer patients within class 1. Additionally, analyses
beyond progression-free survival including freedom from systemic therapy was not available.
Finally, the burden of disease in our study was based on number of metastases. It is possible
that volume of disease, while correlated, may offer additional value in assessing Nevertheless,
our study shows that long-term survivors exist and pre-treatment criteria may facilitate appro-
priate patient selection. Moreover, though statistical methods were used to attempt to maxi-
mize generalizability, our results should be validated on an external independent cohort to
verify its applicability to the general population.
Ongoing studies are necessary to assess the benefit of ablative therapy for oligometastases
and identify biological factors that may further improve patient selection. Recent data suggest
that a microRNA candidate classifier can identify those more likely to survive after HIGRT
[25]. Further analyses to expand on the biology of OM patients are ongoing. Additionally,
NRG-BR001 (NCT02206334) is currently investigating recommended doses for multiple
organ stereotactic ablative radiotherapy, and the randomized phase II SABR-COMET (stereo-
tactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors) has com-
pleted accrual (NCT01446744) [48,49]. Finally, given the strong prognostic weight our
classifier places on primary tumor type and in particular breast cancer histology, our data vali-
date the need to study ablative metastasis-directed therapy in this population, as is being done
in NRG-BR002, randomizing women with 1–2 breast cancer metastases to upfront ablation of
all metastases with either surgery or radiation along with standard of care systemic therapy or
standard of care systemic therapy alone (NCT02364557) [50].
Conclusions
In conclusion, in our large multi-institutional cohort, we found that following ablative radio-
therapy for oligometastatic patients, long-term survivors exist and a sizable fraction do not
progress. We identified prognostic factors for patients undergoing HIGRT for oligometastases.
Patients with breast, prostate, or kidney cancers or long disease-free intervals have promising
outcomes overall. BED was associated with improved clinical outcomes, and improved treated
metastasis control was associated with overall survival.
Supporting information
S1 File. Cox proportional hazards source code.
(R)
S2 File. Recursive partitioning analysis source code.
(R)
Acknowledgments
We would like to acknowledge Ryan Burr for assistance with data extraction and Mary Ann
Schroder for project management.
Prognostic system for oligometastases
PLOS ONE | https://doi.org/10.1371/journal.pone.0195149 April 12, 2018 13 / 17
Author Contributions
Conceptualization: Julian C. Hong, Diandra N. Ayala-Peacock, Jason Lee, A. William Black-
stock, Paul Okunieff, Max W. Sung, Ralph R. Weichselbaum, Johnny Kao, James J. Urbanic,
Michael T. Milano, Steven J. Chmura, Joseph K. Salama.
Data curation: Julian C. Hong.
Formal analysis: Julian C. Hong.
Investigation: Julian C. Hong, Diandra N. Ayala-Peacock, Jason Lee.
Methodology: Julian C. Hong, Joseph K. Salama.
Project administration: Julian C. Hong, Diandra N. Ayala-Peacock, Jason Lee, Johnny Kao,
James J. Urbanic, Michael T. Milano, Steven J. Chmura, Joseph K. Salama.
Resources: A. William Blackstock, Paul Okunieff, Max W. Sung, Ralph R. Weichselbaum,
Johnny Kao, James J. Urbanic, Michael T. Milano, Steven J. Chmura, Joseph K. Salama.
Software: Julian C. Hong.
Supervision: Johnny Kao, Steven J. Chmura, Joseph K. Salama.
Visualization: Julian C. Hong, Joseph K. Salama.
Writing – original draft: Julian C. Hong, Joseph K. Salama.
Writing – review & editing: Julian C. Hong, Diandra N. Ayala-Peacock, Jason Lee, A. William
Blackstock, Paul Okunieff, Max W. Sung, Ralph R. Weichselbaum, Johnny Kao, James J.
Urbanic, Michael T. Milano, Steven J. Chmura, Joseph K. Salama.
References
1. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol. 1994; 12:
2229–2234. https://doi.org/10.1200/JCO.1994.12.10.2229 PMID: 7931493
2. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13: 8–10. https://doi.org/10.1200/
JCO.1995.13.1.8 PMID: 7799047
3. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung
metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113:
37–49. https://doi.org/10.1016/S0022-5223(97)70397-0 PMID: 9011700
4. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal
metastases. J Clin Oncol. 1997; 15: 938–946. https://doi.org/10.1200/JCO.1997.15.3.938 PMID:
9060531
5. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes After Stereotactic
Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016; 34:
452–459. https://doi.org/10.1200/JCO.2015.61.4925 PMID: 26628466
6. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential phase I and II trials of ste-
reotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013; 31:
1631–1639. https://doi.org/10.1200/JCO.2012.44.1659 PMID: 23547075
7. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-
institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally
advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 1128–1137. https://doi.org/10.
1002/cncr.29161 PMID: 25538019
8. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for
localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II
trials. Radiother Oncol. 2013; 109: 217–221. https://doi.org/10.1016/j.radonc.2013.08.030 PMID:
24060175
9. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy
versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised
trials. Lancet Oncol. 2015; 16: 630–637. https://doi.org/10.1016/S1470-2045(15)70168-3 PMID:
25981812
Prognostic system for oligometastases
PLOS ONE | https://doi.org/10.1371/journal.pone.0195149 April 12, 2018 14 / 17
10. Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, et al. Rationale of techni-
cal requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple
metastases. Pract Radiat Oncol. 2016; 6: e291–e298. https://doi.org/10.1016/j.prro.2016.05.004 PMID:
27345129
11. Lewis SL, Porceddu S, Nakamura N, Palma DA, Lo SS, Hoskin P, et al. Definitive Stereotactic Body
Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation
Oncologists. Am J Clin Oncol. 2015. https://doi.org/10.1097/COC.0000000000000169 PMID:
25647831
12. Tong CCL, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, et al. Phase II trial of concurrent
sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE. 2012; 7: e36979. https://doi.
org/10.1371/journal.pone.0036979 PMID: 22761653
13. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, et al. Phase 1 study of concurrent sunitinib
and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases:
acute toxicity and preliminary response. Cancer. 2009; 115: 3571–3580. https://doi.org/10.1002/cncr.
24412 PMID: 19536893
14. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiother-
apy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012; 83: 878–886. https://
doi.org/10.1016/j.ijrobp.2011.08.036 PMID: 22172903
15. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiother-
apy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5
sites of metastatic disease. Cancer. 2012; 118: 2962–2970. https://doi.org/10.1002/cncr.26611 PMID:
22020702
16. de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic
cancer: a prognostic model for survival. Ann Oncol. 2014; 25: 467–471. https://doi.org/10.1093/annonc/
mdt537 PMID: 24355488
17. Høyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on ste-
reotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006; 45: 823–830. https://doi.org/
10.1080/02841860600904854 PMID: 16982546
18. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of
curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions.
Cancer. 2008; 112: 650–658. https://doi.org/10.1002/cncr.23209 PMID: 18072260
19. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institu-
tional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009; 27:
1572–1578. https://doi.org/10.1200/JCO.2008.19.6329 PMID: 19255321
20. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional
phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27: 1579–
1584. https://doi.org/10.1200/JCO.2008.19.6386 PMID: 19255320
21. Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, et al. Phase II study of stereo-
tactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung
cancer patients. Ann Oncol. 2014; 25: 1954–1959. https://doi.org/10.1093/annonc/mdu370 PMID:
25114022
22. Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, et al. Phase II trial of stereotactic body
radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-
cell lung cancer. J Clin Oncol. 2014; 32: 3824–3830. https://doi.org/10.1200/JCO.2014.56.7412 PMID:
25349291
23. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014; 32:
2902–2912. https://doi.org/10.1200/JCO.2014.55.9567 PMID: 25113765
24. Salama JK, Chmura SJ. Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc
Clin Oncol Educ Book. 2015; 35: e8–15. https://doi.org/10.14694/EdBook_AM.2015.35.e8 PMID:
25993242
25. Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, et al. Clinical and molecular markers of
long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;
122: 2242–2250. https://doi.org/10.1002/cncr.30058 PMID: 27206146
26. Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, et al. Radiosensitivity Differences
Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes
After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016; 95: 1399–1404. https://
doi.org/10.1016/j.ijrobp.2016.03.050 PMID: 27319288
27. Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, et al. Differences Between Colon
Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest
Prognostic system for oligometastases
PLOS ONE | https://doi.org/10.1371/journal.pone.0195149 April 12, 2018 15 / 17
Implications for Potential Oligometastatic SBRT Patient Selection. Int J Radiat Oncol Biol Phys. 2015;
92: 837–842. https://doi.org/10.1016/j.ijrobp.2015.01.036 PMID: 25838188
28. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, et al. An initial report of a radia-
tion dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008;
14: 5255–5259. https://doi.org/10.1158/1078-0432.CCR-08-0358 PMID: 18698045
29. Kao J, Chen C- T, Tong CCL, Packer SH, Schwartz M, Chen S- H, et al. Concurrent sunitinib and ste-
reotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
Target Oncol. 2014; 9: 145–153. https://doi.org/10.1007/s11523-013-0280-y PMID: 23660867
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to
evaluate the response to treatment in solid tumors. JNCI Journal of the National Cancer Institute. 2000;
92: 205–216. https://doi.org/10.1093/jnci/92.3.205 PMID: 10655437
31. Hong JC. julianhong/oligometastasis. In: github.com [Internet]. [cited 20 Mar 2018]. Available: https://
github.com/julianhong/oligometastasis
32. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and Regression Trees. London: Chap-
man and Hall/CRC; 1984.
33. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival
and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carci-
noma. J Clin Oncol. 2009; 27: 3584–3590. https://doi.org/10.1200/JCO.2008.20.1293 PMID: 19487381
34. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus inter-
feron alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115–124. https://doi.org/10.
1056/NEJMoa065044 PMID: 17215529
35. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus
Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracy-
cline treatment. J Clin Oncol. 2008; 26: 3950–3957. https://doi.org/10.1200/JCO.2007.11.9362 PMID:
18711184
36. Kress M-AS, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K. Scoring system predictive of sur-
vival for patients undergoing stereotactic body radiation therapy for liver tumors. Radiat Oncol. BioMed
Central; 2012; 7: 148. https://doi.org/10.1186/1748-717X-7-148 PMID: 22950606
37. Guckenberger M, Lang S, Hoyer M, Fode MM. 198PD: Nomogram for predicting overall survival after
stereotactic body radiotherapy for pulmonary metastases: Development and external validation. Journal
of Thoracic . . .; 2016. https://doi.org/10.1016/S1556-0864(16)30307-0
38. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data meta-
analysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung can-
cer. Clin Lung Cancer. 2014; 15: 346–355. https://doi.org/10.1016/j.cllc.2014.04.003 PMID: 24894943
39. Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radio-
therapy for oligo-metastases. Radiother Oncol. 2015; 114: 155–160. https://doi.org/10.1016/j.radonc.
2014.12.003 PMID: 25583567
40. Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, et al. Stereotactic body radiotherapy
(SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "ste-
reotactic radiotherapy". Lung Cancer. 2016; 97: 51–58. https://doi.org/10.1016/j.lungcan.2016.04.012
PMID: 27237028
41. Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, et al. Influence of Institu-
tional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for
Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017; 98: 511–520. https://doi.org/10.
1016/j.ijrobp.2016.09.026 PMID: 27843031
42. Klement RJ, Guckenberger M, Alheid H, Allga¨uer M, Becker G, Blanck O, et al. Stereotactic body radio-
therapy for oligo-metastatic liver disease—Influence of pre-treatment chemotherapy and histology on
local tumor control. Radiother Oncol. 2017; 123: 227–233. https://doi.org/10.1016/j.radonc.2017.01.
013 PMID: 28274491
43. Griffioen GHMJ, Toguri D, Dahele M, Warner A, De Haan PF, Rodrigues GB, et al. Radical treatment of
synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic
factors. Lung Cancer. 2013; 82: 95–102. https://doi.org/10.1016/j.lungcan.2013.07.023 PMID:
23973202
44. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative
therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung
cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol. 2016. https://doi.org/10.1016/S1470-2045(16)30532-0 PMID: 27789196
45. Ruers T, Punt CJA, Van Coevorden F, Pierie J- P, Rinkes IB, Ledermann JA, et al. Radiofrequency
ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM):
Prognostic system for oligometastases
PLOS ONE | https://doi.org/10.1371/journal.pone.0195149 April 12, 2018 16 / 17
Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup
40004 (CLOCC). J Clin Oncol. 2015; 33.
46. Lester-Coll NH, Rutter CE, Bledsoe TJ, Goldberg SB, Decker RH, Yu JB. Cost-Effectiveness of Sur-
gery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. Int
J Radiat Oncol Biol Phys. 2016; 95: 663–672. https://doi.org/10.1016/j.ijrobp.2016.01.020 PMID:
27055395
47. Dagan R, Lo SS, Redmond KJ, Poon I, Foote MC, Lohr F, et al. A multi-national report on stereotactic
body radiotherapy for oligometastases: Patient selection and follow-up. Acta Oncol. 2016; 55: 633–637.
https://doi.org/10.3109/0284186X.2015.1118659 PMID: 27046290
48. Palma DA, Haasbeek CJA, Rodrigues GB, Dahele M, Lock M, Yaremko B, et al. Stereotactic ablative
radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol
for a randomized phase II trial. BMC Cancer. 2012; 12: 305. https://doi.org/10.1186/1471-2407-12-305
PMID: 22823994
49. A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
[Internet]. [cited 1 Jul 2016]. Available: https://clinicaltrials.gov/ct2/show/NCT02206334
50. A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy
(SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer. Available: https://
clinicaltrials.gov/ct2/show/NCT02364557
Prognostic system for oligometastases
PLOS ONE | https://doi.org/10.1371/journal.pone.0195149 April 12, 2018 17 / 17
